20 May 2019 - PHARMAC responds to a request for information relating to the funding of tenofovir disoproxil fumarate with emtricitabine (Truvada) for people who do not have HIV, to prevent HIV (PrEP).

PHARMAC does not hold information on whether people using PrEP have contracted HIV and so is not aware of specific cases where this has occurred. The Ministry of Health may be able to identify whether patients who have had PrEP have then gone onto a regimen for HIV treatment – which could indicate that they had contracted HIV while using PrEP. 

Read PHARMAC response